Company Encyclopedia
View More
name
ABBISKO-B
02256.HK
Abbisko Cayman Limited engages in the research and development of pharmaceutical products in the People’s Republic of China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor in NDA/commercial trial for the treatment of tenosynovial giant cell tumors, as well as chronic graft versus host disease and solid tumors. It is also developing pivotal trial products comprising Mavorixafor (ABSK081), a CXCR4 modulator to treat warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome; and Irpagratinib (ABSK011), a small molecule inhibitor of FGFR4 for the treatment of advanced hepatocellular carcinoma. In addition, the company develops products in Phase Ib/II trial, such as Fexagratinib (ABSK091) for the treatment of urothelial carcinoma; ABSK061, a small molecule inhibitor targeting FGFR 2/3 to treat solid tumors and achondroplasia; and ABSK043, a PD-L1 inhibitor for the treatment of non-small cells lung cancer (NSCLC).
1.290 T
02256.HKMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking7/54
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.88%C
    • Profit Margin24.24%A
    • Gross Margin100.00%A
  • Growth ScoreA
    • Revenue YoY24.63%A
    • Net Profit YoY1027.22%A
    • Total Assets YoY10.06%B
    • Net Assets YoY5.87%B
  • Cash ScoreB
    • Cash Flow Margin412.61%C
    • OCF YoY24.63%A
  • Operating ScoreD
    • Turnover0.26D
  • Debt ScoreA
    • Gearing Ratio8.93%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | ABBISKO-B approaches previous lows, is a rebound window ahead?

    ABBISKO-B (2256.HK) has recently seen a continuous decline in its volatility center, with the daily MACD showing a death cross, indicating a sustained weakening of bullish momentum in the short term. From the market perspective, the stock price is once again approaching the previous low point area, and the support effect is facing a test. The willingness of major funds to flow in is relatively weak, with total trading volume continuously shrinking, and only sporadic funds attempting to gamble at low levels. In terms of technical structure, if the stock price can gain volume support after a period of intensive consolidation, a short-term rebound led by funds is expected. However, if the trading volume shrinks or panic selling occurs, the risk of a plunge cannot be ignored. The current focus of operations should be on observing the effectiveness of support, avoiding inertia declines after support is lost, and then considering active entry. If there are marginal changes in the market environment or policy news, it may serve as a trigger signal. It is recommended to maintain a light position and prioritize waiting for signal confirmation to cope with potential volatility and fund discrepancies

    Technical Forecast·
    HK
    02256
    +2.57%
    Technical Forecast·
    HK
    02256
    +2.57%

    Abbisko Cayman Limited (2256) Receives a Buy from UBS

    UBS analyst maintained a Buy rating on Abbisko Cayman Limited (2256) on November 3, setting a price target of HK$25.20, while the shares closed at HK$14.97. Additionally, Goldman Sachs also issued a Buy rating on October 26. However, TR | OpenAI reiterated a Hold rating on October 31.

    Tip Ranks·
    HK
    02256
    +2.57%
    Tip Ranks·
    HK
    02256
    +2.57%

    UBS initiates coverage on ABBISKO-B with a "Buy" rating and a target price of 25.2 yuan

    UBS initiates coverage on ABBISKO-B with a "Buy" rating and a target price of 25.2 yuan. The report points out that ABBISKO is an undervalued innovative oncology drug company with 12 clinical-stage assets and 10 preclinical candidates. The global licensing agreement with Merck for USD 605.5 million demonstrates its R&D capabilities. UBS's sales forecasts for its core assets pimicotinib and irpagratinib are higher than market expectations, at 8.9 billion and 4.8 billion yuan, respectively

    AASTOCKS·
    HK
    02256
    +2.57%
    AASTOCKS·
    HK
    02256
    +2.57%

    ABBISKO-B completed the administration of the oral small molecule PD-L1 inhibitor ABSK043 in combination with Golaris for the first patient in the Phase II clinical trial for NSCLC

    ABBISKO-B announced that the first patient has been dosed in its Phase II clinical study of the oral small molecule PD-L1 inhibitor ABSK043 in combination with Golaris for the treatment of KRAS G12C mutated non-small cell lung cancer (NSCLC). The study aims to evaluate the safety, tolerability, and efficacy of the combination therapy and was approved by the NMPA in August 2025. The first patient dosing marks an important advancement in clinical development

    Zhitong·
    HK
    02256
    +2.57%
    Zhitong·
    HK
    02256
    +2.57%

    Through the ABBISKO-B R&D Day, we can see the depth and breadth of its FIC/BIC innovative pipeline

    ABBISKO-B has made significant progress in new drug development, with 22 drugs in the pipeline, of which more than 10 have entered the clinical stage. On October 30, the company held its 2025 R&D Day event, bringing together investment institutions, clinical experts, and media to share its innovative R&D layout and clinical progress. CEO Xu Yaochang emphasized the company's commitment to developing differentiated innovative therapies in the fields of oncology and other diseases, showcasing its leadership in the small molecule platform and the endogenous growth of global innovation

    Zhitong·
    HK
    02256
    +2.57%
    Zhitong·
    HK
    02256
    +2.57%
    © 2025 Longbridge｜Disclaimer